The negative correlation (Table 1) between LAPTM4B and most immune checkpoints partially explained the insensitivity of ccRCC to immunotherapy, this evidence suggested that LAPTM4B may promote the growth and metastasis of renal cancer by boosting the immune escape of tumor cells. Here, LAPTM4B is linked to neoplasm.